Mometason Orion (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside nasal epithelial cells. This complex alters gene expression, decreasing the production of inflammatory mediators such as cytokines and chemokines while increasing anti‑inflammatory proteins. The net effect is reduced swelling, mucus production, and immune cell activity in the nasal mucosa.

The appropriate dose of Mometason Orion is determined by the prescribing clinician based on the patient’s age, severity of symptoms, and specific indication. The prescriber will provide exact instructions on how many sprays to use per nostril and the frequency of administration.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting treatment.

To request Mometason Orion, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometason Orion (mometasone furoate) is a high‑potency intranasal corticosteroid with a low systemic absorption profile, similar to fluticasone and budesonide. Compared with some older steroids, it often provides effective symptom control at a lower daily dose, but individual response and tolerability may vary.

Mometason Orion should be stored at room temperature, below 25 °C. Keep the spray bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

The product is a nasal spray. The user gently tilts the head forward, inserts the tip into one nostril, and sprays the prescribed number of sprays while breathing in gently through the nose. The same procedure is repeated in the other nostril if directed by the prescriber.

Serious but rare risks include nasal septal perforation, cataracts or glaucoma with long‑term use, adrenal suppression, and severe hypersensitivity reactions such as angioedema. Patients should report persistent nosebleeds, visual changes, or signs of systemic steroid effects to their healthcare provider promptly.

Mometason Orion is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with untreated fungal infections of the nasal passages or those who have recently undergone nasal surgery until healing is complete.